JPRN-UMIN000020916
Recruiting
未知
Treatment with bevacizumab for ocular vascular lesions - Treatment with bevacizumab for ocular vascular lesions
ConditionsOcular vascular lesions
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Ocular vascular lesions
- Sponsor
- Keio University, School of Medicine
- Enrollment
- 1000
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Those who cannot understand the impact of the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration - NDViasual acuity lossMedDRA version: 9.1Level: SOCClassification code 10015919Term: Eye disordersEUCTR2006-004320-36-ITAZIENDA OSPEDALIERA SENESE
Withdrawn
Phase 3
Intravitreal Bevacizumab for Inflammatory Neovascular MembranesVogt Koyanagi Harada DiseaseSerpiginous ChoroiditisMultifocal ChoroiditisNCT00407121Asociación para Evitar la Ceguera en México
Completed
Not Applicable
Intravitreal bevacizumab treatment for severe retinopathy of prematuritysevere retinopathy of prematurityJPRN-UMIN000018122The Jikei University School of Medicine Department of Ophthalmology6
Not yet recruiting
Phase 2
Role of subconjunctival injection of Bevacizumab (Anti VEGF) for Corneal Neovascularisation,after cornea TransplantHealth Condition 1: - Health Condition 2: H598- Other intraoperative and postprocedural complications and disorders of eye and adnexa, not elsewhere classifiedCTRI/2021/10/037416SNMedical College
Completed
Not Applicable
Intravitreal bevacizumab(Avastin) for macular edema secondary to uveitis: 1 year results of a prospective pilot studyMacular edema secondary to uveitis.Other specified retinal disordersIRCT138902113846N1Shiraz University of Medical Sciences30